mProX™ Human MAPK14 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

MAPK14 (also known as p38 MAPK) is involved in various cellular processes and has applications in different disease contexts. It is implicated in bladder cancer, where it is targeted by Talaroconvolutin-A (TalaA), a compound that suppresses bladder cancer growth by blocking the cell cycle and inducing ferroptosis. MAPK14 is one of the MAPKs to which TalaA binds, inhibiting the phosphorylation of transcription regulators and contributing to the anti-tumor effects of TalaA. Additionally, MAPK14 is identified in the context of glioma, where it is targeted by α-solanine, a compound with anti-tumor activity. Inflammatory diseases are another area of application for MAPK14, as shown by its involvement in the anti-inflammatory activity of fermented pineapple juice and the potential mechanisms of the anti-osteoporotic effects of the Achyranthes bidentata-Dipsacus asper herb pair. Lastly, a potent MAPK13-14 inhibitor is shown to prevent airway inflammation and mucus production, suggesting a potential therapeutic approach for respiratory diseases. Overall, MAPK14 plays a role in multiple disease processes and has implications for targeted therapies.